🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the effort against drug-resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with estimates suggesting over 82 million infections each year. Particularly high rates are seen in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Authorization

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization represents a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

According to data released by a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which involves two antibiotics. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have shared positive views. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is deemed essential to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea around the world.